Front-Line Venetoclax and Obinutuzumab combination followed by Venetoclax or Venetoclax and Zanubrutinib combination in patients with residual disease: a minimal residual disease (MRD) tailored treatment for young patients with high risk CLL. A phase II multicenter study (VIS trial) - Trial 2022-002579-12
Access comprehensive clinical trial information for 2022-002579-12 through Pure Global AI's free database. This phase not specified trial is sponsored by FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS and is currently Ongoing. The study focuses on Chronic Lymphocytic Leukemia.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
BeiGene
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
1. Patients older than18 years and 65 years or less.
ICD-10 Classifications
Data Source
EU Clinical Trials Register
2022-002579-12
Non-Device Trial